Targets › DHODH
7 programs from 7 companies in 13 trials: 5 Phase 2, 5 Phase 1, 3 Phase 3; Neurology, Oncology, Immunology; next expected readout Nov 2026.
Catalyzes the conversion of dihydroorotate to orotate with a quinone as electron acceptor, likely ubiquinone-10. Required for UMP biosynthesis via de novo pathway. (UniProt, Q02127)
Open in Phaseline: the race on DHODH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunic | Vidofludimus (IMU-838) Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 3 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis (RRMS) | Nov 2026 |
| University Hospital, Montpellier | Teriflunomide Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 3 | Relapsing-Remitting Multiple Sclerosis (RRMS) | Jun 2031 |
| City of Hope Medical Center | Leflunomide Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 2 | Smoldering Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Advanced Pancreatic Adenocarcinoma; Acute Graft Versus Host Disease … | Nov 2026 |
| Kiora Pharmaceuticals | KIO-104 Dihydroorotate dehydrogenase (DHODH) inhibitor | DHODH | Phase 2 | Macular Edema | Nov 2026 |
| Peking University People's Hospital | Teriflunomide Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 2 | Immune Thrombocytopenia (ITP) | Sep 2027 |
| Jabez Bioscience | JBZ-001 DHODH inhibitor | DHODH | Phase 1 | Solid Tumor | Feb 2027 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Teriflunomide Dihydroorotate dehydrogenase inhibitor | DHODH | Phase 1 | HAM/TSP | Dec 2027 |
Relapsing-Remitting Multiple Sclerosis (RRMS) (2) Smoldering Plasma Cell Myeloma (1) Recurrent Plasma Cell Myeloma (1) Advanced Pancreatic Adenocarcinoma (1) Acute Graft Versus Host Disease (1) Chronic Graft Versus Host Disease (1) Immune Thrombocytopenia (ITP) (1) Multiple Sclerosis, Relapsing-Remitting (1) Multiple Sclerosis (1) HAM/TSP (1) Solid Tumor (1) Macular Edema (1)
small molecule (6), mixed (1)
City of Hope Medical Center (1) Peking University People's Hospital (1) Immunic (1) National Institute of Neurological Disorders and Stroke (NINDS) (1) University Hospital, Montpellier (1) Jabez Bioscience (1) Kiora Pharmaceuticals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.